Market Overview

UPDATE: Jefferies Lowers PT on Pfizer Following Global Pharma Review

Related PFE
Healthcare Humbled, But Not Knocked Out
Pfizer's Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA® When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate (MCV4) and Tetanus, Diphtheria and Pertussis (Tdap) Vaccines in Adolescents
Eli Lilly Pulls Cholesterol Drug (Investor's Business Daily)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Pfizer (NYSE: PFE), but lowered the price target from $33.00 to $32.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Pfizer closed on Thursday at $27.48.

Latest Ratings for PFE

Oct 2015Morgan StanleyUpgradesEqual-weightOverweight
Aug 2015JefferiesMaintainsBuy
Jun 2015JefferiesInitiates Coverage onOverweight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!

Get Benzinga's Newsletters